BONE MARROW TRANSPLANTATION

Scope & Guideline

Unveiling New Horizons in Bone Marrow Transplantation.

Introduction

Welcome to your portal for understanding BONE MARROW TRANSPLANTATION, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0268-3369
PublisherSPRINGERNATURE
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1986 to 2024
AbbreviationBONE MARROW TRANSPL / Bone Marrow Transplant.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'BONE MARROW TRANSPLANTATION' focuses on the latest advancements and research findings in the field of hematopoietic stem cell transplantation (HSCT) and related cellular therapies. It encompasses a wide range of studies, from clinical trials to epidemiological analyses, aiming to improve the understanding and treatment of hematological malignancies and other disorders through transplantation.
  1. Hematopoietic Stem Cell Transplantation (HSCT):
    The journal emphasizes research on the efficacy, safety, and outcomes of HSCT for various hematological disorders, including leukemia, lymphoma, and myelodysplastic syndromes. This encompasses studies on conditioning regimens, donor selection, and post-transplant care.
  2. Graft-versus-Host Disease (GVHD):
    A significant part of the journal's focus is on the prevention, diagnosis, and treatment of GVHD, a common complication following HSCT. This includes exploring novel prophylactic strategies and therapies for managing acute and chronic GVHD.
  3. Innovative Therapies and Techniques:
    Research on novel cellular therapies such as CAR-T cell therapy, as well as advancements in immunotherapy and targeted therapies, is frequently published, reflecting the journal's commitment to integrating new treatment modalities into clinical practice.
  4. Infectious Complications and Management:
    The journal addresses the challenges of infectious complications in HSCT recipients, including the management of viral reactivations (e.g., CMV, EBV) and bacterial infections, highlighting the importance of prophylactic strategies and treatment protocols.
  5. Patient-Centered Care and Quality of Life:
    Studies examining the psychosocial aspects, quality of life, and long-term outcomes of patients undergoing HSCT are also a critical focus, emphasizing the holistic approach to patient care.
The journal reflects ongoing advancements and shifts in research focus, with several emerging themes gaining attention. These trends indicate the evolving landscape of hematopoietic stem cell transplantation and associated therapies.
  1. Post-Transplant Cyclophosphamide (PTCy):
    There is a growing body of research dedicated to the use of PTCy as a prophylactic treatment in haploidentical stem cell transplantation, highlighting its effectiveness in reducing GVHD and improving transplant outcomes.
  2. CAR-T Cell Therapy:
    The ongoing exploration of CAR-T cell therapy in various hematological malignancies, particularly in relapsed or refractory cases, is a prominent theme, showcasing its integration into transplantation protocols.
  3. Patient Engagement and Quality of Life Research:
    An increasing focus on patient-reported outcomes and quality of life in HSCT recipients signifies a shift towards more patient-centered research, emphasizing the importance of psychosocial factors in treatment success.
  4. Microbiome Research in Transplantation:
    Emerging studies investigating the role of gut microbiota in transplant outcomes and GVHD are gaining traction, reflecting a broader interest in the interplay between microbiome health and patient recovery.
  5. Use of Advanced Imaging and Biomarkers:
    The integration of advanced imaging techniques and biomarker research to predict outcomes post-transplantation is becoming more common, enhancing the ability to tailor treatments to individual patient needs.

Declining or Waning

While 'BONE MARROW TRANSPLANTATION' continues to evolve, certain themes and areas of research are witnessing a decline in prominence. This may reflect shifts in clinical priorities, emerging treatments, or changes in the scientific landscape.
  1. Traditional Conditioning Regimens:
    There is a noticeable decrease in studies focused solely on traditional myeloablative conditioning regimens as researchers increasingly explore reduced-intensity and non-myeloablative approaches, which are becoming more favored in practice.
  2. Single Donor Transplantation Studies:
    Research focusing on single donor transplantation models, particularly in less diverse donor settings, is becoming less common as the field shifts towards exploring haploidentical and mismatched donor strategies, which are gaining traction.
  3. Basic Science Studies on Stem Cell Biology:
    There seems to be a waning interest in basic science research solely focused on stem cell biology without direct clinical applications, as more research is geared towards translational studies and clinical outcomes.
  4. Longitudinal Studies with Limited Sample Sizes:
    The frequency of longitudinal studies with small sample sizes appears to be decreasing, as there is a growing emphasis on larger, multicenter studies that offer more robust data and generalizable findings.

Similar Journals

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Elevating Standards in Clinical Hematology Research
Publisher: ELSEVIER SCI LTDISSN: 1521-6926Frequency: 4 issues/year

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY is a leading academic journal published by ELSEVIER SCI LTD, dedicated to advancing knowledge in the field of clinical hematology. Since its inception in 1999, the journal has provided a platform for high-quality research, offering insights that bridge the gap between clinical practice and breakthrough scientific discoveries. With its significant standing, the journal has garnered a Q2 ranking in both Clinical Biochemistry and Oncology as of 2023, indicating its influence and authority within these domains. Although it does not operate under an open-access model, BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY remains essential for researchers, healthcare professionals, and students looking to stay informed about the latest developments in hematological science. The journal's rigorous peer-review process and commitment to publishing innovative studies make it a cornerstone resource for anyone invested in clinical hematology and related fields.

Hematologie

Connecting Researchers and Clinicians in Hematology
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

Blood Science

Navigating the Complexities of Blood Health
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

AMERICAN JOURNAL OF HEMATOLOGY

Elevating Knowledge in Blood Health and Treatment
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

LIVER TRANSPLANTATION

Exploring New Horizons in Hepatic Care.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1527-6465Frequency: 12 issues/year

LIVER TRANSPLANTATION, published by Lippincott Williams & Wilkins, stands at the forefront of hepatology and transplantation research, with a prestigious Q1 rating across the categories of Hepatology, Surgery, and Transplantation as of 2023. Since its inception in 2000, this journal has been dedicated to disseminating high-quality, cutting-edge research that advances the understanding and practice of liver transplantation. With an impressive ranking of 23rd out of 551 in Surgery and 9th out of 54 in Transplantation, it occupies an esteemed position in the academic landscape, attracting contributions from leading experts in the field. The journal's rigorous peer-review process ensures the publication of impactful studies, innovative clinical practices, and vital insights into patient management. By fostering a collaborative environment for researchers, clinicians, and students alike, LIVER TRANSPLANTATION serves as an essential resource for those engaged in the complexities of liver transplantation and related fields. Join the community committed to advancing liver health and transplantation science.

Hematology Transfusion and Cell Therapy

Fostering collaboration for groundbreaking blood health solutions.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

JOURNAL OF CLINICAL IMMUNOLOGY

Exploring the Dynamics of Immune Responses
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 0271-9142Frequency: 8 issues/year

JOURNAL OF CLINICAL IMMUNOLOGY, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the field of immunology, with an impressive standing as reflected in its Q1 ranking in both Immunology and Immunology and Allergy for 2023. With a history of publication dating back to 1981 and an E-ISSN of 1573-2592, this journal aims to disseminate cutting-edge research on diagnostic methods, therapeutic strategies, and understanding the mechanisms underlying immune responses. Its significant impact is underscored by its Scopus rankings, where it is placed in the top 15% of journals covering immunology and microbiology. The journal does not currently operate under an Open Access model, yet offers a robust platform for sharing essential findings that contribute to advancements in clinical immunology. As a resource for researchers, professionals, and students, the JOURNAL OF CLINICAL IMMUNOLOGY is pivotal in fostering dialogue and disseminating knowledge that enhances our understanding of immune-related diseases.

Transplantation and Cellular Therapy

Empowering Discoveries in Cell Biology and Molecular Medicine.
Publisher: ELSEVIER SCIENCE INCISSN: 2666-6375Frequency: 12 issues/year

Transplantation and Cellular Therapy is a leading journal published by Elsevier Science Inc, dedicated to advancing the fields of transplantation, immunology, cell biology, and molecular medicine. With its ISSN of 2666-6375 and E-ISSN 2666-6367, this journal serves as a vital resource for researchers, practitioners, and students aiming to stay at the forefront of innovative therapies and clinical practices in transplantation. As of 2023, it holds an impressive Q1 ranking in multiple categories, including Cell Biology, Hematology, Immunology and Allergy, Molecular Medicine, and Transplantation, reflecting its high impact and relevance in the scientific community. The journal, operating from its base in the Netherlands, supports Open Access publishing to enhance the dissemination and accessibility of groundbreaking research. Acknowledging the significance of transplantation and cellular therapies in modern medicine, Transplantation and Cellular Therapy is poised to propel future discoveries and developments in these critical domains.

Current Research in Translational Medicine

Driving Progress in Biochemistry, Hematology, and Beyond
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 2452-3186Frequency: 4 issues/year

Current Research in Translational Medicine, published by ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, is a dynamic open-access journal that has been at the forefront of innovative research since its inception in 2016. With a strong commitment to advancing the fields of biochemistry, hematology, infectious diseases, oncology, and transplantation, the journal provides an invaluable platform for researchers and practitioners to share novel findings that bridge laboratory discoveries and clinical applications. Currently recognized in prestigious categories such as Q1 and Q2 quartiles, this journal emphasizes the importance of translational science in improving health outcomes, supported by a rigorous editorial process and a commitment to high-quality research dissemination. Being listed in reputable databases like Scopus, it enables authors to reach a wide audience, ensuring that their impactful work contributes to the global dialogue on critical medical advancements. With its open access model, Current Research in Translational Medicine encourages widespread collaboration and engagement among the scientific community, solidifying its role as a leading journal in medicine and related fields.

Journal of Hematology

Empowering Research, Transforming Lives
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.